Galoretx Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-12-2024
- Paid Up Capital ₹ 0.10 M
as on 25-12-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.02 M
as on 25-12-2024
- Revenue 128.66%
(FY 2022)
- Profit -43.99%
(FY 2022)
- Ebitda 44.58%
(FY 2022)
- Net Worth 2.77%
(FY 2022)
- Total Assets 63.25%
(FY 2022)
About Galoretx Pharmaceuticals
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.02 M.
Raghuveer Ramachandra, Kallajhari Ramachandra, Sasikumar Pottayil, and One other member serve as directors at the Company.
- CIN/LLPIN
U85320KA2018PTC114735
- Company No.
114735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jul 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Udupi, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Galoretx Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sasikumar Pottayil  | Director | 06-Feb-2023 | Current |
| Raghuveer Ramachandra | Whole-Time Director | 12-Jul-2018 | Current |
| Kallajhari Ramachandra | Whole-Time Director | 12-Jul-2018 | Current |
| Chenna Gundala | Director | 06-Feb-2023 | Current |
Financial Performance of Galoretx Pharmaceuticals.
Galoretx Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 128.66% increase. The company also saw a substantial fall in profitability, with a 43.99% decrease in profit. The company's net worth moved up by a moderate rise of 2.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Galoretx Pharmaceuticals?
Unlock access to Galoretx Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Peptis Pharma LlpActive 3 years 7 monthsRaghuveer Ramachandra, Sasikumar Pottayil and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Aug 2024 | ₹7.02 M | Open |
Others Creation Date: 03 Oct 2022 | ₹1.00 M | Open |
How Many Employees Work at Galoretx Pharmaceuticals?
Galoretx Pharmaceuticals has a workforce of 10 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Galoretx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galoretx Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
